Use of Levosimendan in Acute and Advanced Heart Failure: Short Review on Available Real-World Data

Authors

Eugene Pashkovetsky, New York Medical College
Chhaya A. Gupta, New York Medical CollegeFollow
Wilbert S. Aronow, New York Medical CollegeFollow

DOI

10.2147/TCRM.S188761

Journal Title

Therapeutics and Clinical Risk Management

First Page

765

Last Page

772

Document Type

Article

Publication Date

June 2019

Department

Medicine

Abstract

Published data have shown potential advantages of levosimendan in the management of acute decompensated heart failure and advanced heart failure when standard medical therapies threaten hemodynamics and organ perfusion are unable to alleviate clinical symptoms. Levosimendan distinguishes itself from other catecholaminergic inotropes by its three mechanisms of action: positive inotropy, vasodilation, and cardioprotection. In addition, its pharmacokinetics allow for a longer duration of action from the metabolite OR1896 allowing for further cardiovascular therapeutic effects for several days, even after discontinuation of the parent drug.

Recommended Citation

Pashkovetsky, E., Gupta, C. A., & Aronow, W. (2019). Use of Levosimendan in Acute and Advanced Heart Failure: Short Review on Available Real-World Data. Therapeutics and Clinical Risk Management, 15, 765-772. https://doi.org/10.2147/TCRM.S188761